# A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

> **NCT03377179** · PHASE2 · COMPLETED · sponsor: **RedHill Biopharma Limited** · enrollment: 65 (actual)

## Conditions studied

- Cholangiocarcinoma
- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma, Perihilar
- Cholangiocarcinoma, Extrahepatic
- Cholangiocarcinoma, Intrahepatic

## Interventions

- **DRUG:** ABC294640
- **DRUG:** Hydroxychloroquine Sulfate 200 MG

## Key facts

- **NCT ID:** NCT03377179
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-07
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-06-21
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03377179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03377179, "A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03377179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*